Hong Kong Immuno-Oncology 2016

Prof Wu speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the changing aetiology and incidence of lung cancer in China. He describes the developments in surgery and chemotherapy in treating lung cancer patients, and outlines how immunotherapy in adjuvant or neo-adjuvant settings may improve outcomes.

Prof Toh speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about changing attitudes and understanding of immunotherapy. He considers the future development of T cell therapy, and using aspirin for chemoprevention of colorectal cancer progression. Prof Toh also describes the prevalence of EBV nasopharyngeal tumours in Asia, and an ongoing trial of T cell therapy to combat it.

Prof Furuse speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the prospects of treating biliary tract cancer beyond surgical resection. He describes the differing global incidence of biliary tract cancer, and introduces trials of checkpoint inhibitory immunotherapy alongside chemotherapy for treating these tumours.

Prof Mok speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about organising the meeting, and highlights from the scientific programme. He summarises his presentation on developing immunotherapeutics for lung cancer, looking at combinations with chemotherapy and immuno-doublets.

Dr Lee speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the medical advances and financial hurdles in for cancer patients, and oncologists, in Hong Kong. Considering the breadth of sources for disseminating developments in treatments, especially with immunotherapy, she describes the value of peer-learning within institutes and online.

Prof Sakai speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the staging of therapies for metastatic gastric cancer. He outlines which therapy is suited to first and second line therapy, with ongoing research for immunotherapy and targeted molecules work in combination for these patients.

Dr Bang meets with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting to discuss the current status, and future developments, of immunotherapy for treating gastric cancers. He considers PD-1 as biomarker for patient selection and guiding treatment, with ongoing clinical trials to determine its utility.

Dr Chan speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about predisposing factors of developing hepatocellular carcinoma, and how they might be tackled before cancer develops. He describes how vaccines and anti-viral therapies have limited tumourigenic hepatitis infections, and how screening for alpha-fetoprotein or interleukin 10 can provide actionable biomarkers. With regards to immunotherapeutic targets, Dr Chan considers how OX40, VEGF targeting and T cell therapy can improve response in combination with PD-1 checkpoint therapy,

Prof Lordick speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the classifications of gastric cancer, and how they might inform treatment. He outlines known biomarkers for patient subtyping, and considers when sequential treatment, anti-angiogenic therapy or combination therapies might be best used. Prof Lordick also introduces the 2019 Gastric Cancer Congress in Prague.

Dr Welsh speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about combined radio-immunotherapy. He outlines prospective research into using radiation-induced tumour cell death to develop personalised cancer 'vaccines' for patients, and considers the multiple sites of treatment in ongoing trials.

David Johnson meets with ecancertv at Immuno-Oncology Hong Kong 2016 meeting to discuss his experience in training as a medical oncologist.